Avadel Pharmaceuticals PLC reports results for the quarter ended in January - Earnings Summary

Avadel Pharmaceuticals

08/05/2024 16:04

* Avadel Pharmaceuticals PLC  AVDL.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
January, higher than the same quarter last year, when the
company reported EPS of -48 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 21 cents per
share. Wall Street expected results to range from -31 cents
to -1 cents per share.
    * Revenue was $27.18 million​; analysts expected $25.90
million. 
    * Avadel Pharmaceuticals PLC's reported EPS for the quarter
was a
loss of 30 cents​.
    * The company reported a quarterly loss of $27.34 million.
    * Avadel Pharmaceuticals PLC shares had risen by 7.6% this
quarter and gained 28.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 16.3%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Avadel
Pharmaceuticals PLC is $22.50 
This summary was machine generated from LSEG data May 8 at 03:04
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.21          -0.30          Missed
 Dec. 31 2023                     -0.29          
 Sep. 30 2023      -0.37          -0.41          Missed
 Jun. 30 2023      -0.38          -0.83          Missed